RxDoctor Payments Data

Olusoji Afuwape

General Practice · Dallas, TXNPI 1982165155

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Novo Nordisk. That places this record below the midpoint for general practice clinicians in TX, where the typical reported total is $213.

$28in general payments, 2019–2025

Across 1 payment — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$28
$12,316,200in research payments, 2019–2025

Across 97 payments — averaging $126,971 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$8.1M
  • Lexicon Pharmaceuticals, Inc.$1.9M
  • Mirati Therapeutics, Inc.$1.4M
  • Eli Lilly$733K
  • AbbVie$76K
  • Pfizer$55K
  • plus $135K from 4 others

What the payments were for

  • Food & beverage$28100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$28

How this compares

$28 in reported general payments places this provider in the 10th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas →

Other general practice in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →